<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/portal?portalId=9001&amp;quantity=&amp;format=rss&amp;version=">
        <title>BioMed Central - Latest Articles</title>
        <link>http://www.biomedcentral.com/</link>
        <description>The latest research articles published by BioMed Central</description>
        <dc:date>2013-05-25T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.cardiab.com/content/12/1/79" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/content/6/1/210" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2180/13/116" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6963/13/194" />
                                <rdf:li rdf:resource="http://www.virologyj.com/content/10/1/162" />
                                <rdf:li rdf:resource="http://www.molecularbrain.com/content/6/1/27" />
                                <rdf:li rdf:resource="http://respiratory-research.com/content/14/1/57" />
                                <rdf:li rdf:resource="http://www.ijponline.net/content/39/1/34" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/13/149" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2334/13/241" />
                            </rdf:Seq>
        </items>
                 <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.cardiab.com/content/12/1/79">
        <title>HbA1c versus oral glucose tolerance test as a method to diagnose diabetes mellitus in vascular surgery patients</title>
        <description>Background:
The diagnosis of diabetes mellitus (DM) is based on either fasting plasma glucose levels or an oral glucose tolerance test (OGTT). Recently, an HbA1c value of &gt;= 48 mmol/mol (6.5%) has been included as an additional test to diagnose DM. The purpose of this study was to validate HbA1c versus OGTT as a method to diagnose DM in vascular surgery patients.
Methods:
The study population consisted of 345 patients admitted consecutively due to peripheral arterial disease. Sixty-seven patients were previously diagnosed with DM. Glucose levels of OGTT and HbA1c values were analyzed in 275 patients. The OGTT results were categorized into three groups according to the World Health Organization 1999 criteria: 1) DM defined as fasting plasma glucose (FPG) &gt;= 7.0 mmol/L and/or two-hour value (2-h-value) &gt;= 11.1 mmol/L; 2) intermediate hyperglycaemia, which consists of IGT (FPG &lt; 7.0 mmol/L and a 2-h-value between 7.8 mmol/L and 11.1 mmol/L), and IFG (fasting glucose value between 6.1 mmol/L and 7.0 mmol/L with a normal 2-h-value); and 3) normal glucose metabolism defined as FPG &lt; 6.1 mmol/L and a 2-h-value &lt; 7.8 mmol/L.
Results:
Of the 275 patients on whom OGTT was performed, 33 were diagnosed with DM, 90 with intermediate hyperglycaemia and 152 had normal glucose metabolism. An HbA1c value of &gt;= 48 mmol/mol (6.5%) detected DM with a 45.5% sensitivity and a 90% specificity compared with the OGTT results. Combining the measurements of the HbA1c value with the fasting plasma glucose level (&gt;=7.0 mmol/L) increased the sensitivity to 64%. The total prevalence of DM and intermediate hyperglycaemia was 85% based on HbA1c values and 45% based on the OGTT.
Conclusions:
Compared with the OGTT the HbA1c cut-off value of &gt;= 48 mmol/mol (6.5%) had a 45.5% sensitivity to diagnose DM in patients with peripheral arterial disease. OGTT and HbA1c categorized different individuals with DM and intermediate hyperglycaemia. The total prevalence of pathologic glucose metabolism was substantially higher based on HbA1c values than based on OGTT. The high prevalence of DM and intermediate hyperglycaemia when using HbA1c in this study may reflect a high chronic glycaemic burden in patients with peripheral arterial disease. Further studies on vascular surgery patients are needed to identify which method, OGTT or HbA1c, is the better in predicting DM and future clinical development of vascular disease.Trial registration: REK vest 14109</description>
        <link>http://www.cardiab.com/content/12/1/79</link>
                <dc:creator>Irene D Hjellestad</dc:creator>
                <dc:creator>Marianne C Astor</dc:creator>
                <dc:creator>Roy M Nilsen</dc:creator>
                <dc:creator>Eirik Søfteland</dc:creator>
                <dc:creator>Tobjørn Jonung</dc:creator>
                <dc:source>Cardiovascular Diabetology 2013, 12:79</dc:source>
        <dc:date>2013-05-25T00:00:00Z</dc:date>
        <dc:identifier>${item.identifier}</dc:identifier>
                                <prism:require>/content/figures/1475-2840-12-79-toc.gif</prism:require>
                <prism:publicationName>Cardiovascular Diabetology</prism:publicationName>
        <prism:issn>1475-2840</prism:issn>
        <prism:volume>12</prism:volume>
        <prism:startingPage>79</prism:startingPage>
        <prism:publicationDate>2013-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/content/6/1/210">
        <title>Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis</title>
        <description>Background:
Ulcerative colitis (UC) often occurs in women of childbearing age. Compared to Western countries, however, few studies have investigated the impact of UC on the progress of pregnancy in Asian populations.
Methods:
We retrospectively examined 91 pregnancies in 64 patients with UC experienced at our hospital and related institutions from 1991 to 2011, focusing on the relationship between the progression of UC during pregnancy, progress of the pregnancy itself, and the treatment of UC.
Results:
In 80 of 91 pregnancies the patient had already been diagnosed with UC at the time she became pregnant, of whom 31 (38.8%) experienced exacerbation during pregnancy. Regarding severity, moderate or severe active-stage disease during pregnancy was seen in 13.7% of those who had been in remission at the onset of pregnancy versus 58.6% of those who had been in the active stage at onset (OR 8.9: 95%CI 3.0~26.4; P&lt;0.01). The incidence of miscarriage or abortion was 9.8% in pregnancies in which UC was in remission at onset versus 31% in those in which it was in the active stage at onset (OR 4.1: 95%CI 1.2~13.9; P=0.02). Among patients, 62.5% were receiving pharmaceutical treatment at onset of pregnancy. Exacerbation during pregnancy occurred in 26.5% of the group who continued to receive the same treatment during pregnancy versus 56.3% of those with a dose decrease or discontinuation after onset (OR 3.6: 95%CI 1.0~12.4; P=0.04).
Conclusions:
UC patients wishing to conceive should do so when in remission and continue appropriate pharmaceutical treatment during pregnancy.</description>
        <link>http://www.biomedcentral.com/content/6/1/210</link>
                <dc:creator>Masaki Ujihara</dc:creator>
                <dc:creator>Takafumi Ando</dc:creator>
                <dc:creator>Kazuhiro Ishiguro</dc:creator>
                <dc:creator>Osamu Maeda</dc:creator>
                <dc:creator>Osamu Watanabe</dc:creator>
                <dc:creator>Yutaka Hirayama</dc:creator>
                <dc:creator>Kazuhiro Morise</dc:creator>
                <dc:creator>Keiko Maeda</dc:creator>
                <dc:creator>Masanobu Matsushita</dc:creator>
                <dc:creator>Ryoji Miyahara</dc:creator>
                <dc:creator>Naoki Ohmiya</dc:creator>
                <dc:creator>Yuji Nishio</dc:creator>
                <dc:creator>Takeo Yamaguchi</dc:creator>
                <dc:creator>Jun-ichi Haruta</dc:creator>
                <dc:creator>Kenji Ina</dc:creator>
                <dc:creator>Hidemi Goto</dc:creator>
                <dc:source>BMC Research Notes 2013, 6:210</dc:source>
        <dc:date>2013-05-25T00:00:00Z</dc:date>
        <dc:identifier>${item.identifier}</dc:identifier>
                                <prism:require>/content/figures/1756-0500-6-210-toc.gif</prism:require>
                <prism:publicationName>BMC Research Notes</prism:publicationName>
        <prism:issn>1756-0500</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>210</prism:startingPage>
        <prism:publicationDate>2013-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2180/13/116">
        <title>Human milk metagenome: a functional capacity analysis</title>
        <description>Background:
Human milk contains a diverse population of bacteria that likely influences colonization of the infant gastrointestinal tract. Recent studies, however, have been limited to characterization of this microbial community by 16S rRNA analysis. In the present study, a metagenomic approach using Illumina sequencing of a pooled milk sample (ten donors) was employed to determine the genera of bacteria and the types of bacterial open reading frames in human milk that may influence bacterial establishment and stability in this primal food matrix. The human milk metagenome was also compared to that of breastfed and formula-fed infants&apos; feces (n = 5, each) and mothers&apos; feces (n = 3) at the phylum level and at a functional level using open reading frame abundance. Additionally, immune-modulatory bacterial-DNA motifs were also searched for within human milk.
Results:
The bacterial community in human milk contained over 360 prokaryotic genera, with sequences aligning predominantly to the phyla of Proteobacteria (65%) and Firmicutes (34%), and the genera of Pseudomonas (61.1%), Staphylococcus (33.4%) and Streptococcus (0.5%). From assembled human milk-derived contigs, 30,128 open reading frames were annotated and assigned to functional categories. When compared to the metagenome of infants&apos; and mothers&apos; feces, the human milk metagenome was less diverse at the phylum level, and contained more open reading frames associated with nitrogen metabolism, membrane transport and stress response (P &lt; 0.05). The human milk metagenome also contained a similar occurrence of immune-modulatory DNA motifs to that of infants&apos; and mothers&apos; fecal metagenomes.
Conclusions:
Our results further expand the complexity of the human milk metagenome and enforce the benefits of human milk ingestion on the microbial colonization of the infant gut and immunity. Discovery of immune-modulatory motifs in the metagenome of human milk indicates more exhaustive analyses of the functionality of the human milk metagenome are warranted.</description>
        <link>http://www.biomedcentral.com/1471-2180/13/116</link>
                <dc:creator>Tonya L Ward</dc:creator>
                <dc:creator>Sergey Hosid</dc:creator>
                <dc:creator>Ilya Ioshikhes</dc:creator>
                <dc:creator>Illimar Altosaar</dc:creator>
                <dc:source>BMC Microbiology 2013, 13:116</dc:source>
        <dc:date>2013-05-25T00:00:00Z</dc:date>
        <dc:identifier>${item.identifier}</dc:identifier>
                                <prism:require>/content/figures/1471-2180-13-116-toc.gif</prism:require>
                <prism:publicationName>BMC Microbiology</prism:publicationName>
        <prism:issn>1471-2180</prism:issn>
        <prism:volume>13</prism:volume>
        <prism:startingPage>116</prism:startingPage>
        <prism:publicationDate>2013-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6963/13/194">
        <title>Evaluation of the theory-based Quality Improvement in Physical Therapy (QUIP) programme: a one-group, pre-test post-test pilot study</title>
        <description>Background:
Guideline adherence in physical therapy is far from optimal, which has consequences for the effectiveness and efficiency of physical therapy care. Programmes to enhance guideline adherence have, so far, been relatively ineffective. We systematically developed a theory-based Quality Improvement in Physical Therapy (QUIP) programme aimed at the individual performance level (practicing physiotherapists; PTs) and the practice organization level (practice quality manager; PQM). The aim of the study was to pilot test the multilevel QUIP programme&apos;s effectiveness and the fidelity, acceptability and feasibility of its implementation.
Methods:
A one-group, pre-test, post-test pilot study (N = 8 practices; N = 32 PTs, 8 of whom were also PQMs) done between September and December 2009. Guideline adherence was measured using clinical vignettes that addressed 12 quality indicators reflecting the guidelines&apos; main recommendations. Determinants of adherence were measured using quantitative methods (questionnaires). Delivery of the programme and management changes were assessed using qualitative methods (observations, group interviews, and document analyses). Changes in adherence and determinants were tested in the paired samples T-tests and expressed in effect sizes (Cohen&apos;s d).
Results:
Overall adherence did not change (3.1%; p = .138). Adherence to three quality indicators improved (8%, 24%, 43%; .000 &lt;= p &lt;= .023). Adherence to one quality indicator decreased (-15.7%; p = .004). Scores on various determinants of individual performance improved and favourable changes at practice organizational level were observed. Improvements were associated with the programme&apos;s multilevel approach, collective goal setting, and the application of self-regulation; unfavourable findings with programme deficits. The one-group pre-test post-test design limits the internal validity of the study, the self-selected sample its external validity.
Conclusions:
The QUIP programme has the potential to change physical therapy practice but needs considerable revision to induce the ongoing quality improvement process that is required to optimize overall guideline adherence. To assess its value, the programme needs to be tested in a randomized controlled trial.</description>
        <link>http://www.biomedcentral.com/1472-6963/13/194</link>
                <dc:creator>Geert M Rutten</dc:creator>
                <dc:creator>Janneke Harting</dc:creator>
                <dc:creator>L Kay Bartholomew</dc:creator>
                <dc:creator>Angelique Schlief</dc:creator>
                <dc:creator>Rob AB Oostendorp</dc:creator>
                <dc:creator>Nanne K de Vries</dc:creator>
                <dc:source>BMC Health Services Research 2013, 13:194</dc:source>
        <dc:date>2013-05-25T00:00:00Z</dc:date>
        <dc:identifier>${item.identifier}</dc:identifier>
                                <prism:require>/content/figures/1472-6963-13-194-toc.gif</prism:require>
                <prism:publicationName>BMC Health Services Research</prism:publicationName>
        <prism:issn>1472-6963</prism:issn>
        <prism:volume>13</prism:volume>
        <prism:startingPage>194</prism:startingPage>
        <prism:publicationDate>2013-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.virologyj.com/content/10/1/162">
        <title>Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice</title>
        <description>AimTo evaluate the efficacy and safety of Entecavir (ETV) plus adefovir (ADV) for chronic hepatitis B (CHB) patients after multiple nucleos(t)ide analogue (NAs) failure treatment.
Methods:
Hepatitis B e antigen (HBeAg)-positive patients who had a suboptimal response or developed resistance to two or more previous NAs treatments were included, and all subjects were treated with ETV in combination with ADV for &gt;= 24 months. Complete virologic response (CVR) was defined as an undetectability of serum hepatitis B virus (HBV) DNA level during treatment. Safety assessment was based on the increasing of serum creatinine and creatine kinase levels.
Results:
A total of 45 eligible patients were included. Twenty-five patients had been treated with lamivudine (LAM) or telbivudine (LdT) and developed genotypic resistance. Resistance to ADV was present in 18 patients and 4 patients had a suboptimal response to ETV. Two patients had a resistance to both LAM and ADV. The cumulative probabilities of CVR at 12 and 24 months of ETV + ADV treatment were 88.9% (40/45) and 97.8% (44/45), respectively. Although one patient failed to achieve CVR, its serum HBV DNA level decreased by 3.3 log copies/mL after 24 months of combination therapy. The cumulative probability of HBeAg seroconversion was 15.6% (7/45) and 26.7% (12/45) at 12 and 24 months of treatment, respectively. History of prior exposure to specific NAs did not make a difference to ETV + ADV treatment outcome. There were no significant adverse events related to ETV + ADV therapy observed in the study subjects.
Conclusion:
ETV + ADV can be used as an effective and safe rescue therapy in patients after multiple NA therapy failures, especially in the areas where tenofovir is not yet available.</description>
        <link>http://www.virologyj.com/content/10/1/162</link>
                <dc:creator>Xian-Hua Xu</dc:creator>
                <dc:creator>Gai-Li Li</dc:creator>
                <dc:creator>Yang Qin</dc:creator>
                <dc:creator>Qiang Li</dc:creator>
                <dc:creator>Fa-Qun He</dc:creator>
                <dc:creator>Jin-Ye Li</dc:creator>
                <dc:creator>Quan-Rong Pan</dc:creator>
                <dc:creator>Jie-Yin Deng</dc:creator>
                <dc:source>Virology Journal 2013, 10:162</dc:source>
        <dc:date>2013-05-25T00:00:00Z</dc:date>
        <dc:identifier>${item.identifier}</dc:identifier>
                                <prism:require>/content/figures/1743-422X-10-162-toc.gif</prism:require>
                <prism:publicationName>Virology Journal</prism:publicationName>
        <prism:issn>1743-422X</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>162</prism:startingPage>
        <prism:publicationDate>2013-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularbrain.com/content/6/1/27">
        <title>Neurological characterization of mice deficient in GSK3alpha highlight pleiotropic physiological functions in cognition and pathological activity as Tau kinase</title>
        <description>Background:
GSK3beta is involved in a wide range of physiological functions, and is presumed to act in the pathogenesis of neurological diseases, from bipolar disorder to Alzheimer&apos;s disease (AD). In contrast, the GSK3alpha isozyme remained largely ignored with respect to both aspects.
Results:
We generated and characterized two mouse strains with neuron-specific or with total GSK3alpha deficiency. Behavioral and electrophysiological analysis demonstrated the physiological importance of neuronal GSK3alpha, with GSK3beta not compensating for impaired cognition and reduced LTP. Interestingly, the passive inhibitory avoidance task proved to modulate the phosphorylation status of both GSK3 isozymes in wild-type mice, further implying both to function in cognition. Moreover, GSK3alpha contributed to the neuronal architecture of the hippocampal CA1 sub-region that is most vulnerable in AD. Consequently, practically all parameters and characteristics indicated that both GSK3 isoforms were regulated independently, but that they acted on the same physiological functions in learning and memory, in mobility and in behavior.
Conclusions:
GSK3alpha proved to be regulated independently from GSK3beta, and to exert non-redundant physiological neurological functions in general behavior and in cognition. Moreover, GSK3alpha contributes to the pathological phosphorylation of protein Tau.</description>
        <link>http://www.molecularbrain.com/content/6/1/27</link>
                <dc:creator>Hervé Maurin</dc:creator>
                <dc:creator>Benoit Lechat</dc:creator>
                <dc:creator>Ilse Dewachter</dc:creator>
                <dc:creator>Laurence Ris</dc:creator>
                <dc:creator>Justin V Louis</dc:creator>
                <dc:creator>Peter Borghgraef</dc:creator>
                <dc:creator>Herman Devijver</dc:creator>
                <dc:creator>Tomasz Jaworski</dc:creator>
                <dc:creator>Fred Van Leuven</dc:creator>
                <dc:source>Molecular Brain 2013, 6:27</dc:source>
        <dc:date>2013-05-25T00:00:00Z</dc:date>
        <dc:identifier>${item.identifier}</dc:identifier>
                                <prism:require>/content/figures/1756-6606-6-27-toc.gif</prism:require>
                <prism:publicationName>Molecular Brain</prism:publicationName>
        <prism:issn>1756-6606</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>27</prism:startingPage>
        <prism:publicationDate>2013-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://respiratory-research.com/content/14/1/57">
        <title>Higher serum CCL17 may be a promising predictor of acute exacerbations in chronic hypersensitivity pneumonitis</title>
        <description>Background:
Recent research has suggested that the Th1 and Th2 chemokine/cytokine axis contributes to the development of chronic hypersensitivity pneumonitis (HP). Acute exacerbations (AE) are significant factors in the prognosis of chronic HP. Little is known, however, about these biomarkers in association with AE in chronic HP patients.
Methods:
Fifty-six patients with chronic HP were evaluated, including 14 patients during episodes of AE. Th1 mediators (C-X-C chemokine ligand [CXCL]10 and interferon [IFN]-gamma), Th2 mediators (C-C chemokine ligand [CCL]17, interleukin-4, and interleukin-13), and pro-fibrotic mediator (transforming growth factor [TGF]-beta) were measured to evaluate the mediators as predictors of AE. C-C chemokine receptor (CCR)4 (receptor for CCL17)-positive lymphocytes were quantified in lung specimens.
Results:
Serum CCL17 levels at baseline independently predicted the first episode of AE (HR, 72.0; 95% CI, 5.03-1030.23; p = 0.002). AE was significantly more frequent in the higher-CCL17 group (&gt;=285 pg/ml) than in the lower-CCL17 group (&lt;285 pg/ml) (log-rank test, p = 0.0006; 1-year incidence: higher CCL17 vs. lower CCL17, 14.3% vs. 0.0%). Serum CCL17 levels and CCR4-positive cells during episodes of AE were increased from the baseline (p = 0.01 and 0.031).
Conclusions:
Higher serum concentrations of CCL17 at baseline may be predictive of AE in patients with chronic HP, and CCL17 may contribute to the pathology of AE by inducing the accumulation of CCR4-positive lymphocytes in the lungs.</description>
        <link>http://respiratory-research.com/content/14/1/57</link>
                <dc:creator>Yasunari Miyazaki</dc:creator>
                <dc:creator>Koji Unoura</dc:creator>
                <dc:creator>Tomoya Tateishi</dc:creator>
                <dc:creator>Takumi Akashi</dc:creator>
                <dc:creator>Tamiko Takemura</dc:creator>
                <dc:creator>Makoto Tomita</dc:creator>
                <dc:creator>Naohiko Inase</dc:creator>
                <dc:creator>Yasuyuki Yoshizawa</dc:creator>
                <dc:source>Respiratory Research 2013, 14:57</dc:source>
        <dc:date>2013-05-25T00:00:00Z</dc:date>
        <dc:identifier>${item.identifier}</dc:identifier>
                                <prism:require>/content/figures/1465-9921-14-57-toc.gif</prism:require>
                <prism:publicationName>Respiratory Research</prism:publicationName>
        <prism:issn>1465-9921</prism:issn>
        <prism:volume>14</prism:volume>
        <prism:startingPage>57</prism:startingPage>
        <prism:publicationDate>2013-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.ijponline.net/content/39/1/34">
        <title>Epidemiology and associations with climatic conditions of Mycoplasma pneumoniae and Chlamydophila pneumoniae infections among Chinese children hospitalized with acute respiratory infections</title>
        <description>Background:
The incidence of severe acute respiratory tract infections in children caused by Mycoplasma pneumoniae (syn. Schizoplasma pneumoniae) and Chlamydophila pneumoniae (formerly Chlamydia pneumoniae) varies greatly from year to year and place to place around the world. This study investigated the epidemiology of M. pneumoniae and C. pneumoniae infections among children hospitalized with acute respiratory infections in Suzhou, China in the year 2006, and associations between incidence rates and climatic conditions.
Methods:
Nasopharyngeal aspirates obtained from 1598 patients (aged 26.4 +/- 28.3 months; range, 1 month to 13 years) were analyzed with real-time PCR and ELISA. Meteorological data were obtained from the weather bureau.
Results:
About 18.5% of patients were infected with M. pneumoniae and, C. pneumoniae, or both. Isolated M. pneumoniae infection was positively correlated with increasing age (chi2 = 34.76, P &lt; 0.0001). Incidence of M. pneumoniae infection was seasonal with a peak in summer (P &lt; 0.0001) and minimum in winter (P = 0.0001), whereas C. pneumoniae infection was low only in autumn (P = 0.02). Monthly mean temperature was strongly correlated with the incidence of M. pneumoniae infection (r = 0.825, P = 0.001).
Conclusions:
M. pneumoniae and C. pneumoniae are important infectious agents in hospitalized children with acute respiratory tract infections. M. pneumoniae infection showed a strong direct correlation with environmental temperature.</description>
        <link>http://www.ijponline.net/content/39/1/34</link>
                <dc:creator>Zhengrong Chen</dc:creator>
                <dc:creator>Wei Ji</dc:creator>
                <dc:creator>Yuqing Wang</dc:creator>
                <dc:creator>Yongdong Yan</dc:creator>
                <dc:creator>Hong Zhu</dc:creator>
                <dc:creator>Xuejun Shao</dc:creator>
                <dc:creator>Jun Xu</dc:creator>
                <dc:source>Italian Journal of Pediatrics 2013, 39:34</dc:source>
        <dc:date>2013-05-25T00:00:00Z</dc:date>
        <dc:identifier>${item.identifier}</dc:identifier>
                                <prism:require>/content/figures/1824-7288-39-34-toc.gif</prism:require>
                <prism:publicationName>Italian Journal of Pediatrics</prism:publicationName>
        <prism:issn>1824-7288</prism:issn>
        <prism:volume>39</prism:volume>
        <prism:startingPage>34</prism:startingPage>
        <prism:publicationDate>2013-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/13/149">
        <title>&apos;Pseudoneurological&apos; symptoms, dissociation and stress-related psychopathology in healthy young adults</title>
        <description>Background:
Somatoform dissociation is a specific form of dissociation with somatic manifestations represented in the form of &apos;pseudoneurological&apos; symptoms due to disturbances or alterations of normal integrated functions of consciousness, memory or identity mainly related to trauma and other psychological stressors. With respect to the distinction between psychological and somatoform manifestations of dissociation current data suggest a hypothesis to which extent mild manifestations of &apos;pseudoneurological&apos; symptoms in healthy young population may be linked to stress-related psychopathological symptoms or whether these symptoms more likely could be attributed to unexplained somatic factors.
Methods:
With this aim we have assessed the relationship between somatoform dissociation and stress-related psychopathology (i.e. anxiety, depression, symptoms of traumatic stress, alexithymia) in a group of 250 healthy non-psychiatric and non-clinical young adults.
Results:
Results of this study show that the symptoms of somatoform dissociation are significantly linked to stress-related psychopathology.
Conclusions:
Findings of this study show that the &apos;pseudoneurological&apos; symptoms may be linked to stress-related psychopathological processes which indicate that also mild levels of stress may influence somatic feelings and may lead to various somatoform dissociative symptoms.</description>
        <link>http://www.biomedcentral.com/1471-244X/13/149</link>
                <dc:creator>Petr Bob</dc:creator>
                <dc:creator>Petra Selesova</dc:creator>
                <dc:creator>Ji¿í Raboch</dc:creator>
                <dc:creator>Lubomir Kukla</dc:creator>
                <dc:source>BMC Psychiatry 2013, 13:149</dc:source>
        <dc:date>2013-05-25T00:00:00Z</dc:date>
        <dc:identifier>${item.identifier}</dc:identifier>
                                <prism:require>/content/figures/1471-244X-13-149-toc.gif</prism:require>
                <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>13</prism:volume>
        <prism:startingPage>149</prism:startingPage>
        <prism:publicationDate>2013-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2334/13/241">
        <title>Mycobacterium abscessus isolated from municipal water - a potential source of human infection</title>
        <description>Background:
Mycobacterium abscessus is a rapidly growing mycobacterium responsible for progressive pulmonary disease, soft tissue and wound infections. The incidence of disease due to M. abscessus has been increasing in Queensland. In a study of Brisbane drinking water, M. abscessus was isolated from ten different locations.The aim of this study was to compare genotypically the M. abscessus isolates obtained from water to those obtained from human clinical specimens.
Methods:
Between 2007 and 2009, eleven isolates confirmed as M. abscessus were recovered from potable water, one strain was isolated from a rainwater tank and another from a swimming pool and two from domestic taps. Seventy-four clinical isolates referred during the same time period were available for comparison using rep-PCR strain typing (Diversilab).
Results:
The drinking water isolates formed two clusters with &gt;=97% genetic similarity (Water patterns 1 and 2). The tankwater isolate (WP4), one municipal water isolate (WP3) and the pool isolate (WP5) were distinctly different. Patient isolates formed clusters with all of the water isolates except for WP3. Further patient isolates were unrelated to the water isolates.
Conclusion:
The high degree of similarity between strains of M. abscessus from potable water and strains causing infection in humans from the same geographical area, strengthens the possibility that drinking water may be the source of infection in these patients.</description>
        <link>http://www.biomedcentral.com/1471-2334/13/241</link>
                <dc:creator>Rachel Thomson</dc:creator>
                <dc:creator>Carla Tolson</dc:creator>
                <dc:creator>Hanna Sidjabat</dc:creator>
                <dc:creator>Flavia Huygens</dc:creator>
                <dc:creator>Megan Hargreaves</dc:creator>
                <dc:source>BMC Infectious Diseases 2013, 13:241</dc:source>
        <dc:date>2013-05-25T00:00:00Z</dc:date>
        <dc:identifier>${item.identifier}</dc:identifier>
                                <prism:require>/content/figures/1471-2334-13-241-toc.gif</prism:require>
                <prism:publicationName>BMC Infectious Diseases</prism:publicationName>
        <prism:issn>1471-2334</prism:issn>
        <prism:volume>13</prism:volume>
        <prism:startingPage>241</prism:startingPage>
        <prism:publicationDate>2013-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
